Gelsolin levels are decreased in ankylosing spondylitis patients undergoing anti-TNF-alpha therapy

To determine whether circulating gelsolin (GSN) levels in patients with ankylosing spondylitis (AS) undergoing TNF-α antagonist-infliximab-therapy are altered compared with controls and to establish whether disease activity, systemic inflammation and metabolic syndrome are potential determinants of...

Full description

Saved in:
Bibliographic Details
Published in:Clinical and experimental rheumatology 2014-03, Vol.32 (2), p.218-224
Main Authors: Genre, F, López-Mejías, R, Miranda-Filloy, J A, Ubilla, B, Carnero-López, B, Gómez-Acebo, I, Blanco, R, Ochoa, R, Rueda-Gotor, J, González-Juanatey, C, Llorca, J, González-Gay, M A
Format: Article
Language:English
Subjects:
Adipokines - metabolism
Adult
Antibodies, Monoclonal - administration & dosage
Antibodies, Monoclonal - adverse effects
Antirheumatic Agents - administration & dosage
Antirheumatic Agents - adverse effects
Dose-Response Relationship, Drug
Drug Monitoring
Female
Gelsolin - metabolism
Humans
Inflammation - drug therapy
Infliximab
Infusions, Intravenous
Male
Metabolism - drug effects
Middle Aged
Outpatients
Patient Acuity
Sex Factors
Spondylitis, Ankylosing - drug therapy
Spondylitis, Ankylosing - metabolism
Spondylitis, Ankylosing - physiopathology
Statistics as Topic
Treatment Outcome
Tumor Necrosis Factor-alpha - antagonists & inhibitors
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 224
container_issue 2
container_start_page 218
container_title Clinical and experimental rheumatology
container_volume 32
creator Genre, F
López-Mejías, R
Miranda-Filloy, J A
Ubilla, B
Carnero-López, B
Gómez-Acebo, I
Blanco, R
Ochoa, R
Rueda-Gotor, J
González-Juanatey, C
Llorca, J
González-Gay, M A
description To determine whether circulating gelsolin (GSN) levels in patients with ankylosing spondylitis (AS) undergoing TNF-α antagonist-infliximab-therapy are altered compared with controls and to establish whether disease activity, systemic inflammation and metabolic syndrome are potential determinants of circulating GSN levels in these patients. We assessed GSN serum concentrations in a series of 30 non-diabetic AS patients without cardiovascular (CV) disease undergoing TNF-α antagonist-infliximab therapy and 48 matched controls. GSN levels were measured immediately before and after an infliximab infusion. Correlations of GSN serum levels with disease activity, systemic inflammation and metabolic syndrome were assessed. Potential changes in GSN concentration following an infusion of anti-TNF-α monoclonal antibody-infliximab were also analysed. Although at the time of the study AS patients undergoing anti-TNF-α therapy had adequate control of the disease (mean BASDAI 2.94), they showed lower GSN serum levels than healthy controls (mean±SD: 38660.42±23624.6 ng/ml versus 68975.43±31246.79 ng/ml; p
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1517877425</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1517877425</sourcerecordid><originalsourceid>FETCH-LOGICAL-p211t-b17c3c893544985353fdcc99211dd0cacdd1e664b29eb06539646ea16c3a5e4f3</originalsourceid><addsrcrecordid>eNo1kD1PwzAYhD2AaCn8BeSRJVIcfyQeUUULUgVLkdgix37TGlzH2A5S_j1BlOlO95xuuAu0LKmsioaL9wW6TumjLCvBRX2FFhWjnDDKlqjbgkuDsx47-J4tVhGwAR1BJTB4zpX_nNyQrD_gFAZvJmezTTiobMHnhEdvIB6GX658tsX-ZVMoF44K5yNEFaYbdNkrl-D2rCv0tnncr5-K3ev2ef2wK0JFSC46UmuqG0k5Y7LhlNPeaC3lDI0ptdLGEBCCdZWErhScSsEEKCI0VRxYT1fo_m83xOFrhJTbk00anFMehjG1hJO6qWtW8bl6d66O3QlMG6I9qTi1_7_QH9NwX28</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1517877425</pqid></control><display><type>article</type><title>Gelsolin levels are decreased in ankylosing spondylitis patients undergoing anti-TNF-alpha therapy</title><source>Freely Accessible Journals</source><creator>Genre, F ; López-Mejías, R ; Miranda-Filloy, J A ; Ubilla, B ; Carnero-López, B ; Gómez-Acebo, I ; Blanco, R ; Ochoa, R ; Rueda-Gotor, J ; González-Juanatey, C ; Llorca, J ; González-Gay, M A</creator><creatorcontrib>Genre, F ; López-Mejías, R ; Miranda-Filloy, J A ; Ubilla, B ; Carnero-López, B ; Gómez-Acebo, I ; Blanco, R ; Ochoa, R ; Rueda-Gotor, J ; González-Juanatey, C ; Llorca, J ; González-Gay, M A</creatorcontrib><description>To determine whether circulating gelsolin (GSN) levels in patients with ankylosing spondylitis (AS) undergoing TNF-α antagonist-infliximab-therapy are altered compared with controls and to establish whether disease activity, systemic inflammation and metabolic syndrome are potential determinants of circulating GSN levels in these patients. We assessed GSN serum concentrations in a series of 30 non-diabetic AS patients without cardiovascular (CV) disease undergoing TNF-α antagonist-infliximab therapy and 48 matched controls. GSN levels were measured immediately before and after an infliximab infusion. Correlations of GSN serum levels with disease activity, systemic inflammation and metabolic syndrome were assessed. Potential changes in GSN concentration following an infusion of anti-TNF-α monoclonal antibody-infliximab were also analysed. Although at the time of the study AS patients undergoing anti-TNF-α therapy had adequate control of the disease (mean BASDAI 2.94), they showed lower GSN serum levels than healthy controls (mean±SD: 38660.42±23624.6 ng/ml versus 68975.43±31246.79 ng/ml; p&lt;0.0001). When AS patients were stratified according to sex, we observed that GSN levels were significantly lower in men than in women (p=0.032). However, no differences in GSN levels according to the specific clinical features of the disease were seen. No association was found between GSN concentration and adipokines or biomarkers of endothelial cell activation. However, correlation between basal GSN levels and insulin resistance was observed. A single infliximab infusion did not lead to significant changes in GSN levels. GSN concentration is reduced in AS patients undergoing periodical anti-TNF-α therapy and low disease activity. Potential association with some metabolic syndrome features seems to exist.</description><identifier>ISSN: 0392-856X</identifier><identifier>PMID: 24351434</identifier><language>eng</language><publisher>Italy</publisher><subject>Adipokines - metabolism ; Adult ; Antibodies, Monoclonal - administration &amp; dosage ; Antibodies, Monoclonal - adverse effects ; Antirheumatic Agents - administration &amp; dosage ; Antirheumatic Agents - adverse effects ; Dose-Response Relationship, Drug ; Drug Monitoring ; Female ; Gelsolin - metabolism ; Humans ; Inflammation - drug therapy ; Infliximab ; Infusions, Intravenous ; Male ; Metabolism - drug effects ; Middle Aged ; Outpatients ; Patient Acuity ; Sex Factors ; Spondylitis, Ankylosing - drug therapy ; Spondylitis, Ankylosing - metabolism ; Spondylitis, Ankylosing - physiopathology ; Statistics as Topic ; Treatment Outcome ; Tumor Necrosis Factor-alpha - antagonists &amp; inhibitors</subject><ispartof>Clinical and experimental rheumatology, 2014-03, Vol.32 (2), p.218-224</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24351434$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Genre, F</creatorcontrib><creatorcontrib>López-Mejías, R</creatorcontrib><creatorcontrib>Miranda-Filloy, J A</creatorcontrib><creatorcontrib>Ubilla, B</creatorcontrib><creatorcontrib>Carnero-López, B</creatorcontrib><creatorcontrib>Gómez-Acebo, I</creatorcontrib><creatorcontrib>Blanco, R</creatorcontrib><creatorcontrib>Ochoa, R</creatorcontrib><creatorcontrib>Rueda-Gotor, J</creatorcontrib><creatorcontrib>González-Juanatey, C</creatorcontrib><creatorcontrib>Llorca, J</creatorcontrib><creatorcontrib>González-Gay, M A</creatorcontrib><title>Gelsolin levels are decreased in ankylosing spondylitis patients undergoing anti-TNF-alpha therapy</title><title>Clinical and experimental rheumatology</title><addtitle>Clin Exp Rheumatol</addtitle><description>To determine whether circulating gelsolin (GSN) levels in patients with ankylosing spondylitis (AS) undergoing TNF-α antagonist-infliximab-therapy are altered compared with controls and to establish whether disease activity, systemic inflammation and metabolic syndrome are potential determinants of circulating GSN levels in these patients. We assessed GSN serum concentrations in a series of 30 non-diabetic AS patients without cardiovascular (CV) disease undergoing TNF-α antagonist-infliximab therapy and 48 matched controls. GSN levels were measured immediately before and after an infliximab infusion. Correlations of GSN serum levels with disease activity, systemic inflammation and metabolic syndrome were assessed. Potential changes in GSN concentration following an infusion of anti-TNF-α monoclonal antibody-infliximab were also analysed. Although at the time of the study AS patients undergoing anti-TNF-α therapy had adequate control of the disease (mean BASDAI 2.94), they showed lower GSN serum levels than healthy controls (mean±SD: 38660.42±23624.6 ng/ml versus 68975.43±31246.79 ng/ml; p&lt;0.0001). When AS patients were stratified according to sex, we observed that GSN levels were significantly lower in men than in women (p=0.032). However, no differences in GSN levels according to the specific clinical features of the disease were seen. No association was found between GSN concentration and adipokines or biomarkers of endothelial cell activation. However, correlation between basal GSN levels and insulin resistance was observed. A single infliximab infusion did not lead to significant changes in GSN levels. GSN concentration is reduced in AS patients undergoing periodical anti-TNF-α therapy and low disease activity. Potential association with some metabolic syndrome features seems to exist.</description><subject>Adipokines - metabolism</subject><subject>Adult</subject><subject>Antibodies, Monoclonal - administration &amp; dosage</subject><subject>Antibodies, Monoclonal - adverse effects</subject><subject>Antirheumatic Agents - administration &amp; dosage</subject><subject>Antirheumatic Agents - adverse effects</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug Monitoring</subject><subject>Female</subject><subject>Gelsolin - metabolism</subject><subject>Humans</subject><subject>Inflammation - drug therapy</subject><subject>Infliximab</subject><subject>Infusions, Intravenous</subject><subject>Male</subject><subject>Metabolism - drug effects</subject><subject>Middle Aged</subject><subject>Outpatients</subject><subject>Patient Acuity</subject><subject>Sex Factors</subject><subject>Spondylitis, Ankylosing - drug therapy</subject><subject>Spondylitis, Ankylosing - metabolism</subject><subject>Spondylitis, Ankylosing - physiopathology</subject><subject>Statistics as Topic</subject><subject>Treatment Outcome</subject><subject>Tumor Necrosis Factor-alpha - antagonists &amp; inhibitors</subject><issn>0392-856X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><recordid>eNo1kD1PwzAYhD2AaCn8BeSRJVIcfyQeUUULUgVLkdgix37TGlzH2A5S_j1BlOlO95xuuAu0LKmsioaL9wW6TumjLCvBRX2FFhWjnDDKlqjbgkuDsx47-J4tVhGwAR1BJTB4zpX_nNyQrD_gFAZvJmezTTiobMHnhEdvIB6GX658tsX-ZVMoF44K5yNEFaYbdNkrl-D2rCv0tnncr5-K3ev2ef2wK0JFSC46UmuqG0k5Y7LhlNPeaC3lDI0ptdLGEBCCdZWErhScSsEEKCI0VRxYT1fo_m83xOFrhJTbk00anFMehjG1hJO6qWtW8bl6d66O3QlMG6I9qTi1_7_QH9NwX28</recordid><startdate>20140301</startdate><enddate>20140301</enddate><creator>Genre, F</creator><creator>López-Mejías, R</creator><creator>Miranda-Filloy, J A</creator><creator>Ubilla, B</creator><creator>Carnero-López, B</creator><creator>Gómez-Acebo, I</creator><creator>Blanco, R</creator><creator>Ochoa, R</creator><creator>Rueda-Gotor, J</creator><creator>González-Juanatey, C</creator><creator>Llorca, J</creator><creator>González-Gay, M A</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20140301</creationdate><title>Gelsolin levels are decreased in ankylosing spondylitis patients undergoing anti-TNF-alpha therapy</title><author>Genre, F ; López-Mejías, R ; Miranda-Filloy, J A ; Ubilla, B ; Carnero-López, B ; Gómez-Acebo, I ; Blanco, R ; Ochoa, R ; Rueda-Gotor, J ; González-Juanatey, C ; Llorca, J ; González-Gay, M A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p211t-b17c3c893544985353fdcc99211dd0cacdd1e664b29eb06539646ea16c3a5e4f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adipokines - metabolism</topic><topic>Adult</topic><topic>Antibodies, Monoclonal - administration &amp; dosage</topic><topic>Antibodies, Monoclonal - adverse effects</topic><topic>Antirheumatic Agents - administration &amp; dosage</topic><topic>Antirheumatic Agents - adverse effects</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug Monitoring</topic><topic>Female</topic><topic>Gelsolin - metabolism</topic><topic>Humans</topic><topic>Inflammation - drug therapy</topic><topic>Infliximab</topic><topic>Infusions, Intravenous</topic><topic>Male</topic><topic>Metabolism - drug effects</topic><topic>Middle Aged</topic><topic>Outpatients</topic><topic>Patient Acuity</topic><topic>Sex Factors</topic><topic>Spondylitis, Ankylosing - drug therapy</topic><topic>Spondylitis, Ankylosing - metabolism</topic><topic>Spondylitis, Ankylosing - physiopathology</topic><topic>Statistics as Topic</topic><topic>Treatment Outcome</topic><topic>Tumor Necrosis Factor-alpha - antagonists &amp; inhibitors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Genre, F</creatorcontrib><creatorcontrib>López-Mejías, R</creatorcontrib><creatorcontrib>Miranda-Filloy, J A</creatorcontrib><creatorcontrib>Ubilla, B</creatorcontrib><creatorcontrib>Carnero-López, B</creatorcontrib><creatorcontrib>Gómez-Acebo, I</creatorcontrib><creatorcontrib>Blanco, R</creatorcontrib><creatorcontrib>Ochoa, R</creatorcontrib><creatorcontrib>Rueda-Gotor, J</creatorcontrib><creatorcontrib>González-Juanatey, C</creatorcontrib><creatorcontrib>Llorca, J</creatorcontrib><creatorcontrib>González-Gay, M A</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical and experimental rheumatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Genre, F</au><au>López-Mejías, R</au><au>Miranda-Filloy, J A</au><au>Ubilla, B</au><au>Carnero-López, B</au><au>Gómez-Acebo, I</au><au>Blanco, R</au><au>Ochoa, R</au><au>Rueda-Gotor, J</au><au>González-Juanatey, C</au><au>Llorca, J</au><au>González-Gay, M A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Gelsolin levels are decreased in ankylosing spondylitis patients undergoing anti-TNF-alpha therapy</atitle><jtitle>Clinical and experimental rheumatology</jtitle><addtitle>Clin Exp Rheumatol</addtitle><date>2014-03-01</date><risdate>2014</risdate><volume>32</volume><issue>2</issue><spage>218</spage><epage>224</epage><pages>218-224</pages><issn>0392-856X</issn><abstract>To determine whether circulating gelsolin (GSN) levels in patients with ankylosing spondylitis (AS) undergoing TNF-α antagonist-infliximab-therapy are altered compared with controls and to establish whether disease activity, systemic inflammation and metabolic syndrome are potential determinants of circulating GSN levels in these patients. We assessed GSN serum concentrations in a series of 30 non-diabetic AS patients without cardiovascular (CV) disease undergoing TNF-α antagonist-infliximab therapy and 48 matched controls. GSN levels were measured immediately before and after an infliximab infusion. Correlations of GSN serum levels with disease activity, systemic inflammation and metabolic syndrome were assessed. Potential changes in GSN concentration following an infusion of anti-TNF-α monoclonal antibody-infliximab were also analysed. Although at the time of the study AS patients undergoing anti-TNF-α therapy had adequate control of the disease (mean BASDAI 2.94), they showed lower GSN serum levels than healthy controls (mean±SD: 38660.42±23624.6 ng/ml versus 68975.43±31246.79 ng/ml; p&lt;0.0001). When AS patients were stratified according to sex, we observed that GSN levels were significantly lower in men than in women (p=0.032). However, no differences in GSN levels according to the specific clinical features of the disease were seen. No association was found between GSN concentration and adipokines or biomarkers of endothelial cell activation. However, correlation between basal GSN levels and insulin resistance was observed. A single infliximab infusion did not lead to significant changes in GSN levels. GSN concentration is reduced in AS patients undergoing periodical anti-TNF-α therapy and low disease activity. Potential association with some metabolic syndrome features seems to exist.</abstract><cop>Italy</cop><pmid>24351434</pmid><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0392-856X
ispartof Clinical and experimental rheumatology, 2014-03, Vol.32 (2), p.218-224
issn 0392-856X
language eng
recordid cdi_proquest_miscellaneous_1517877425
source Freely Accessible Journals
subjects Adipokines - metabolism
Adult
Antibodies, Monoclonal - administration & dosage
Antibodies, Monoclonal - adverse effects
Antirheumatic Agents - administration & dosage
Antirheumatic Agents - adverse effects
Dose-Response Relationship, Drug
Drug Monitoring
Female
Gelsolin - metabolism
Humans
Inflammation - drug therapy
Infliximab
Infusions, Intravenous
Male
Metabolism - drug effects
Middle Aged
Outpatients
Patient Acuity
Sex Factors
Spondylitis, Ankylosing - drug therapy
Spondylitis, Ankylosing - metabolism
Spondylitis, Ankylosing - physiopathology
Statistics as Topic
Treatment Outcome
Tumor Necrosis Factor-alpha - antagonists & inhibitors
title Gelsolin levels are decreased in ankylosing spondylitis patients undergoing anti-TNF-alpha therapy
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T01%3A01%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Gelsolin%20levels%20are%20decreased%20in%20ankylosing%20spondylitis%20patients%20undergoing%20anti-TNF-alpha%20therapy&rft.jtitle=Clinical%20and%20experimental%20rheumatology&rft.au=Genre,%20F&rft.date=2014-03-01&rft.volume=32&rft.issue=2&rft.spage=218&rft.epage=224&rft.pages=218-224&rft.issn=0392-856X&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E1517877425%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-p211t-b17c3c893544985353fdcc99211dd0cacdd1e664b29eb06539646ea16c3a5e4f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1517877425&rft_id=info:pmid/24351434&rfr_iscdi=true